Evidence map›Paper›PMID 41290659›Full record

ArticleNature communications2025

State-selective small molecule degraders that preferentially remove aggregates and oligomers.

Jakub Luptak, Dean Clift, Aamir Mukadam, Jonathan Benn, Tyler Rhinesmith, Stephen H McLaughlin, Amy C Dodds, Jerson E Lapetaje, Matylda Sczaniecka-Clift, David J France and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jakub Luptak *MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK.
Dean Clift *MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK.
Aamir MukadamUK Dementia Research Institute at the University of Cambridge, Department of Clinical Neurosciences, Hills Road, Cambridge, UK.
Jonathan BennUK Dementia Research Institute at the University of Cambridge, Department of Clinical Neurosciences, Hills Road, Cambridge, UK.
Tyler RhinesmithMRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK.ORCID http://orcid.org/0000-0002-9983-0287
Stephen H McLaughlinMRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK.ORCID http://orcid.org/0000-0001-9135-6253
Amy C DoddsSchool of Chemistry, Joseph Black Building, University of Glasgow, Glasgow, UK.
Jerson E LapetajeSchool of Chemistry, Joseph Black Building, University of Glasgow, Glasgow, UK.
Matylda Sczaniecka-CliftMRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK.
David J FranceSchool of Chemistry, Joseph Black Building, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0000-0002-5409-3316
William A McEwanUK Dementia Research Institute at the University of Cambridge, Department of Clinical Neurosciences, Hills Road, Cambridge, UK.ORCID http://orcid.org/0000-0002-4408-0407
Leo C JamesMRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK. lcj@mrc-lmb.cam.ac.uk.ORCID http://orcid.org/0000-0003-2131-0334

Funding

Wellcome Trust 223054Wellcome Trust (Wellcome) 223054/Z/21/Z
6 · The paper itself

Abstract

TRIM21 is a unique E3 ligase that uses a clustering-based activation mechanism to degrade complex multimeric substrates. This activity underpins the targeted protein degradation technology Trim-Away and genetically encoded degraders that selectively target aggregated tau protein and prevent tauopathy. Here we describe small molecules that mimic TRIM21's natural epitope and function as either effective inhibitors or potent and selective degraders called TRIMTACs. TRIMTACs mediate degradation as rapidly as PROTACs but can also selectively degrade specific protein pools depending on assembly state. We demonstrate the utility of this state-specific degradation by selectively removing the pro-inflammatory signalling protein Myd88 when assembled into the Myddosome and the cell-death protein RIPK3 when polymerised into the Necrosome. We further show that TRIMTACs can inhibit seeded tau aggregation under conditions where a PROTAC is ineffective. These results highlight that TRIM21's clustering-based activation can be exploited by small molecule degraders to carry out state-selective degradation of therapeutic targets.

Indexed as

Protein AggregatesProteolysisRibonucleoproteinsSmall Molecule Librariestau ProteinsUbiquitin-Protein LigasesAnimalsHEK293 CellsHumansReceptor-Interacting Protein Serine-Threonine KinasesSS-A AntigenProtein AggregatesReceptor-Interacting Protein Serine-Threonine KinasesRibonucleoproteinsSmall Molecule LibrariesSS-A Antigentau ProteinsUbiquitin-Protein Ligases

Identifiers

PMID41290659
PMCPMC12647892

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.